1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

奥西默替尼 医学 肺癌 肿瘤科 非小细胞肺癌 内科学 中期分析 生物标志物 癌症 临床试验 腺癌 A549电池 化学 生物化学 ROS1型
作者
Helena A. Yu,Helen Ambrose,Christina S. Baik,B.C. Cho,Emiliano Cocco,Sarah B. Goldberg,Jonathan W. Goldman,Silvija Kraljevic,Adrianus J. de Langen,Isamu Okamoto,Zofia Piotrowska,Michael Pluta,S. Powar,N. Reguart Aransay,Jonathan W. Riess,Xiuning Le
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:32: S978-S979 被引量:41
标识
DOI:10.1016/j.annonc.2021.08.1844
摘要

Most pts with epidermal growth factor receptor mutation-positive (EGFRm) NSCLC treated with osimertinib, a third-generation, irreversible, CNS-active EGFR-tyrosine kinase inhibitor (TKI), eventually develop resistance. MET alterations are common resistance mechanisms to osimertinib. The phase II ORCHARD platform study (NCT03944772) aims to characterise 1L osimertinib resistance mechanisms and identify optimal post-progression therapies. This interim analysis reports use of osimertinib + savolitinib, an oral, potent and highly selective MET-TKI, in adults with EGFRm advanced NSCLC and MET alterations (MET amplification / MET exon 14 skipping). Pts were allocated to treatment cohorts after disease progression on 1L osimertinib, based on molecular profiling of a tumour biopsy with NGS. Pts whose tumours harbour MET alterations were allocated to osimertinib 80 mg qd + savolitinib 300 or 600 mg qd. Primary endpoint: investigator assessed objective response rate (ORR; RECIST v1.1). Other endpoints include duration of response and safety / tolerability. Interim data cut-off (DCO): Jan 2021. Of 20 pts that received osimertinib + savolitinib, median duration on prior 1L osimertinib was 414 (197–1722) days. At DCO, 17 pts were evaluable for confirmed response. ORR was 41% (n=7; 80% CI: 25, 59); 7 pts (41%) had partial response, 7 (41%) had stable disease and 1 (6%) had disease progression as their best response; 2 pts (12%) were not evaluable. Overall, 6 / 20 pts (30%) reported a grade ≥3 adverse event (AE), most commonly pneumonia and decreased neutrophil count (each n=2; 10%); 6 / 20 pts (30%) reported a serious AE. Three pts (15%) discontinued combination treatment due to AEs. No deaths due to AEs were reported. Osimertinib + savolitinib showed preliminary activity in pts with MET alterations after 1L osimertinib. Based on interim efficacy, enrolment will continue to 30 pts as pre-specified per protocol. The safety profile was acceptable and consistent with known profiles of osimertinib / savolitinib. Further exploration of this combination is underway in the SAVANNAH study (NCT03778229).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
冯俊杰发布了新的文献求助10
1秒前
领导范儿应助cong采纳,获得10
1秒前
眯眯眼的黎昕完成签到 ,获得积分10
2秒前
愉快小凝完成签到,获得积分10
2秒前
科研通AI6.2应助左右脑采纳,获得10
2秒前
3秒前
4秒前
SciGPT应助ziiiiiii7采纳,获得10
4秒前
Ava应助hh采纳,获得10
6秒前
zzz发布了新的文献求助10
6秒前
7秒前
魔幻的惜灵完成签到 ,获得积分10
7秒前
7秒前
7秒前
7秒前
FashionBoy应助科研通管家采纳,获得10
8秒前
SunGuangkai发布了新的文献求助10
8秒前
8秒前
顾矜应助科研通管家采纳,获得10
8秒前
8秒前
乐乐应助科研通管家采纳,获得10
8秒前
8秒前
9秒前
9秒前
9秒前
桐桐应助科研通管家采纳,获得10
9秒前
NexusExplorer应助隐形便当采纳,获得10
9秒前
Lucas应助科研通管家采纳,获得10
9秒前
JamesPei应助科研通管家采纳,获得10
10秒前
桐桐应助科研通管家采纳,获得10
10秒前
传奇3应助科研通管家采纳,获得10
10秒前
李健的小迷弟应助lin采纳,获得10
11秒前
小蘑菇应助冯俊杰采纳,获得10
11秒前
卓奕雯完成签到 ,获得积分10
11秒前
淡定小懒猪完成签到,获得积分10
12秒前
西西弗完成签到 ,获得积分10
12秒前
13秒前
水凤A发布了新的文献求助10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
HYDROLYSE ACIDE DE QUELQUES DIOXASPIROCYCLANES 1314
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Organizational Behavior 510
Management and the Arts 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7747863
求助须知:如何正确求助?哪些是违规求助? 9296136
关于积分的说明 20233622
捐赠科研通 7329210
什么是DOI,文献DOI怎么找? 3308722
关于科研通互助平台的介绍 2460470
邀请新用户注册赠送积分活动 2320668